➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Moodys
McKesson
Harvard Business School
Merck

Last Updated: May 30, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for KAE609


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug KAE609?

KAE609 is an investigational drug.

There have been 6 clinical trials for KAE609. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2013.

The most common disease conditions in clinical trials are Malaria, Malaria, Falciparum, and Malaria, Vivax. The leading clinical trial sponsors are Novartis Pharmaceuticals, This trial is supported in part by Wellcome Trust via Grant # Grant Number 217692/Z/19/Z, and Medicine for Malaria Venture.

There are three US patents protecting this investigational drug and sixty-three international patents.

Recent Clinical Trials for KAE609
TitleSponsorPhase
Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy SubjectsThis trial is supported in part by Wellcome Trust via Grant # Grant Number 217692/Z/19/ZPhase 1
Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy SubjectsNovartis PharmaceuticalsPhase 1
Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.Novartis PharmaceuticalsPhase 2

See all KAE609 clinical trials

Clinical Trial Summary for KAE609

Top disease conditions for KAE609
Top clinical trial sponsors for KAE609

See all KAE609 clinical trials

US Patents for KAE609

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
KAE609   Start Trial Organic compounds Novartis AG (Basel, CH)   Start Trial
KAE609   Start Trial Organic compounds Novartis AG (Basel, CH)   Start Trial
KAE609   Start Trial Chemical process for preparing spiroindolones and intermediates thereof Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for KAE609

Drugname Country Document Number Estimated Expiration Related US Patent
KAE609 Argentina 071222 2028-04-29   Start Trial
KAE609 Australia 2009242279 2028-04-29   Start Trial
KAE609 Brazil PI0911577 2028-04-29   Start Trial
KAE609 Canada 2719365 2028-04-29   Start Trial
KAE609 Chile 2009001007 2028-04-29   Start Trial
KAE609 China 102015711 2028-04-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Moodys
Mallinckrodt
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.